Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$1.50 USD
+0.07 (4.90%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.50 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRNS 1.50 +0.07(4.90%)
Will MRNS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRNS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRNS
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
MRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Posts New Data From Bone Disease Study
SAGE's Huntington's Disease Study Meets Primary Endpoint
AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag
Other News for MRNS
Class Action Lawsuit against Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)
Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
Marinus Pharmaceuticals announces China NMPA approval for ganaxolone
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) Urged to Join Class Action – Contact Levi & Korsinsky LLP to Learn More
Hold Rating on Marinus’s IV Ganaxolone Amid Regulatory and Commercial Uncertainty